Oxaliplatin as a radiosensitizing agent in rectal cancer

Sergio Huerta, John Hrom

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.

Original languageEnglish (US)
Pages (from-to)317-323
Number of pages7
JournalAnti-Cancer Drugs
Volume22
Issue number4
DOIs
Publication statusPublished - Apr 2011

    Fingerprint

Keywords

  • Abdominoperineal resection
  • cisplatin
  • low anterior resection
  • pathological complete response

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this